Received Feb 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | KB2YT | IM / LA |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
generalized hives; generalized rash; This non-serious case was reported by a consumer via call center representative and described the occurrence of generalized urticaria in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix on an unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, 2 weeks after receiving Shingrix, the patient experienced generalized urticaria (Verbatim: generalized hives) and generalized rash (Verbatim: generalized rash). The outcome of the generalized urticaria and generalized rash were unknown. It was unknown if the reporter considered the generalized urticaria and generalized rash to be related to Shingrix. It was unknown if the company considered the generalized urticaria and generalized rash to be related to Shingrix. Additional Information: GSK Receipt Date: 27-JAN-2025 The patient self-reported this case for herself. The patient reported that 2 weeks after she received the second Shingrix vaccine she started to experience generalized hives and rash.